Skip to main content
Image coming soon

GEN0408 Mastering Therapeutic Candidate Selection

$199.00
Adding to cart… The item has been added

The Executive Diagnostic and Governance Toolkit

Mastering Therapeutic Candidate Selection

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which therapeutic candidates to advance into clinical trials based on preclinical data.

$199 one-time
30-day money-back guarantee Verified against latest insights, updated access provided within 24h

Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.

What you walk out with
A scored, ranked picture of your own function, and a defensible answer to what to fix first.
1 You stop guessing where you stand.
You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis.
2 You can defend the decision.
You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language.
3 The work actually moves.
The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total.
4 You use it the day it lands.
No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over.
The Quick Scan is one sitting. You will know your weakest area before the day is out.
Nothing in it is generic project management: the build rejects any file that could belong to another course. Updated after you enrol, so it reflects where the work stands now. The 144-chapter course is included behind it, for the parts you want to go deeper on.
Every candidate advancement decision carries millions in investment and years of momentum—yet relies on incomplete preclinical signals.

The situation this is built for

Therapeutic candidate selection is the most consequential judgment call in biopharmaceutical development. The data is always incomplete. Mechanisms are partially understood. Toxicity signals are ambiguous. Stakeholders have competing priorities. And yet, you must decide: advance or terminate. Make the wrong call and you waste resources, delay breakthroughs, and erode stakeholder trust. Make the right call without a rigorous process and you risk institutionalizing luck over discipline. This moment—between preclinical insight and clinical commitment—is where development leadership is tested.

Who this is for

Chief development officer in a biopharmaceutical organization responsible for therapeutic candidate advancement decisions, overseeing cross-functional teams, and delivering a robust clinical pipeline.

Who this is not for

This is not for scientists focused solely on assay design, nor for clinical operations leads managing trial execution. It is not for vendors selling decision-support tools or platforms. It is for the executive who owns the end-to-end assessment and selection process.

What you walk away with

  • Define clear, evidence-based criteria for candidate advancement
  • Improve consistency in go/no-go decision-making across programs
  • Strengthen cross-functional alignment before candidate review meetings
  • Reduce time spent debating data interpretations during portfolio reviews
  • Build a defensible, auditable selection process for board and regulatory scrutiny

How this maps to your situation

  • Assessing current decision quality
  • Strengthening evidence evaluation
  • Aligning stakeholder inputs
  • Building future-ready systems

Before vs. after

Before
Therapeutic candidate decisions are inconsistent, debated in silos, and vulnerable to bias and incomplete data interpretation.
After
Your organization applies a rigorous, transparent, and defensible process to every advancement decision, grounded in science and aligned to strategy.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 3 hours per module, designed to be completed alongside active candidate reviews. Full course completion in 8–12 weeks with implementation.

If nothing changes
Without a structured approach, candidate selection remains vulnerable to cognitive bias, inconsistent standards, and stakeholder conflict—leading to poor portfolio outcomes, wasted resources, and diminished credibility with investors and regulators.

How this compares to the alternatives

Unlike generic leadership courses or vendor-led toolkits, this program focuses exclusively on the scientific, organizational, and governance dimensions of therapeutic candidate selection—providing actionable frameworks you can implement immediately without dependency on third-party platforms.

Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)

Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.

Module 1. The Strategic Weight of Candidate Selection
Establish the organizational and scientific stakes of choosing which therapeutic candidates move forward.
12 chapters in this module
  1. Understanding the long-term impact of early development decisions
  2. Mapping the cost of advancing a flawed candidate
  3. Identifying key decision inflection points in the development lifecycle
  4. Defining the role of the chief development officer in portfolio shaping
  5. Aligning therapeutic selection with corporate strategic goals
  6. Recognizing the downstream effects of ambiguous go/no-go criteria
  7. Assessing how candidate decisions affect investor and board confidence
  8. Differentiating between scientific promise and clinical viability
  9. Evaluating the opportunity cost of terminated development paths
  10. Integrating risk tolerance into candidate advancement frameworks
  11. Documenting historical decision patterns across past programs
  12. Benchmarking current selection rigor against industry expectations
Module 2. Deconstructing Preclinical Data Packages
Learn how to extract meaningful signals from complex, incomplete datasets.
12 chapters in this module
  1. Structuring a comprehensive preclinical data review checklist
  2. Interpreting in vitro potency data in physiological context
  3. Evaluating pharmacokinetic profiles for translational relevance
  4. Assessing target engagement evidence across model systems
  5. Distinguishing robust biodistribution patterns from noise
  6. Reviewing toxicology findings for clinical red flags
  7. Integrating safety margins into candidate risk scoring
  8. Applying exposure-response relationships to dose projections
  9. Critiquing study design limitations in animal models
  10. Weighing mechanistic plausibility against empirical results
  11. Synthesizing multi-assay data into a unified summary
  12. Identifying data gaps that require mitigation before advancement
Module 3. Building Evidence Thresholds for Advancement
Define what constitutes sufficient evidence to move forward.
12 chapters in this module
  1. Setting minimum efficacy benchmarks from preclinical models
  2. Establishing acceptable safety margins for first-in-human dosing
  3. Determining required duration of toxicology studies
  4. Validating biomarker performance for clinical monitoring
  5. Requiring reproducibility across independent experiments
  6. Defining acceptable levels of off-target activity
  7. Setting bar for in vivo functional response magnitude
  8. Specifying pharmacokinetic parameters for human prediction
  9. Requiring demonstration of target modulation in tissue
  10. Assessing formulation stability for clinical readiness
  11. Evaluating manufacturability constraints early in selection
  12. Documenting evidence thresholds in decision governance documents
Module 4. Designing the Candidate Review Meeting
Structure high-leverage meetings that drive clarity, not debate.
12 chapters in this module
  1. Crafting a pre-read package that enables focused discussion
  2. Setting clear decision objectives for each review session
  3. Defining roles for clinical, toxicology, and CMC leads
  4. Creating standardized templates for candidate data presentation
  5. Eliminating open-ended questions from agenda items
  6. Requiring advance position statements from key stakeholders
  7. Structuring time allocation to prioritize risk assessment
  8. Incorporating silent review periods to reduce groupthink
  9. Designing decision logs to track rationale over time
  10. Managing dissent through structured challenge protocols
  11. Aligning legal and IP considerations into advancement criteria
  12. Ensuring board-level summaries are derived from meeting outputs
Module 5. Modeling Clinical Translation Confidence
Quantify the likelihood that preclinical findings will hold in humans.
12 chapters in this module
  1. Evaluating species-specific differences in target expression
  2. Assessing predictive value of animal disease models
  3. Estimating human dose from preclinical pharmacokinetics
  4. Projecting therapeutic index using safety margins
  5. Validating assay comparability across species
  6. Accounting for protein binding differences in exposure estimates
  7. Incorporating allometric scaling with physiological adjustments
  8. Judging relevance of disease pathophysiology across models
  9. Weighing target conservation in human versus preclinical species
  10. Factoring in immune system differences in xenograft models
  11. Adjusting for metabolic pathway divergence in clearance predictions
  12. Documenting assumptions in translation models for audit purposes
Module 6. Scoring Candidate Viability Across Domains
Implement a multidimensional scoring system grounded in science and strategy.
12 chapters in this module
  1. Defining scoring dimensions for efficacy, safety, and developability
  2. Weighting domains based on therapeutic area risk profile
  3. Normalizing scores across disparate assay types
  4. Assigning confidence levels to individual data points
  5. Incorporating expert judgment into scoring algorithms
  6. Creating visual dashboards for executive review
  7. Requiring justification for outlier score assignments
  8. Validating scoring consistency across multiple reviewers
  9. Linking score thresholds to decision gates
  10. Updating scores dynamically as new data emerges
  11. Archiving scoring records for regulatory and audit purposes
  12. Training teams on standardized scoring interpretation
Module 7. Managing Stakeholder Alignment and Influence
Navigate competing priorities and build consensus without compromising rigor.
12 chapters in this module
  1. Identifying key influencers in the candidate selection process
  2. Mapping reporting relationships that affect decision dynamics
  3. Anticipating functional biases in data interpretation
  4. Engaging toxicology leadership before formal review
  5. Involving CMC experts early in developability assessment
  6. Facilitating clinical team input on trial feasibility
  7. Managing pressure from investor-facing communications
  8. Addressing therapeutic area champion over-enthusiasm
  9. Balancing speed-to-clinic with risk mitigation needs
  10. Resolving conflicts between preclinical and clinical leaders
  11. Establishing escalation paths for unresolved disagreements
  12. Documenting stakeholder positions for decision traceability
Module 8. Integrating Regulatory Readiness Early
Ensure advancement decisions support future regulatory success.
12 chapters in this module
  1. Aligning nonclinical package scope with regulatory expectations
  2. Incorporating ICH guidelines into study design requirements
  3. Planning genotoxicity and safety pharmacology assessments early
  4. Ensuring toxicology species selection meets regulatory standards
  5. Validating bioanalytical methods for GLP compliance
  6. Designing reproductive toxicity studies with regulatory endpoints
  7. Preparing for CMC questions during candidate review
  8. Documenting impurity profiles for regulatory submission
  9. Building comparability protocols for future formulation changes
  10. Anticipating regulatory requests for additional preclinical data
  11. Engaging regulatory strategy leads before advancement
  12. Mapping current data to future IND/IMPD dossier sections
Module 9. Creating Go/No-Go Decision Frameworks
Turn judgment calls into repeatable, defensible processes.
12 chapters in this module
  1. Defining mandatory stop conditions for candidate termination
  2. Setting minimum evidence bars for clinical advancement
  3. Creating conditional go decisions with milestone triggers
  4. Designing escape clauses for emerging safety concerns
  5. Specifying data requirements for first-in-human protocols
  6. Establishing thresholds for pharmacodynamic marker validation
  7. Requiring risk mitigation plans for known liabilities
  8. Incorporating competitive landscape analysis into go decisions
  9. Building decision trees for multi-indication candidates
  10. Setting expiration dates on conditional advancement approvals
  11. Linking decision frameworks to portfolio resource planning
  12. Auditing past decisions to refine future frameworks
Module 10. Documenting Rationale for Future Audits
Create an auditable trail that withstands regulatory and investor scrutiny.
12 chapters in this module
  1. Structuring decision memos with standardized sections
  2. Capturing dissenting opinions in official records
  3. Archiving preclinical data packages with version control
  4. Linking decisions to specific study findings and dates
  5. Writing rationale summaries for non-scientific stakeholders
  6. Maintaining audit logs of changes to candidate status
  7. Storing electronic signatures for key approvals
  8. Ensuring document retention policies meet regulatory standards
  9. Preparing for internal compliance reviews of selection history
  10. Generating board-ready summaries from decision archives
  11. Integrating document systems with enterprise content management
  12. Training staff on documentation requirements for legal defensibility
Module 11. Scaling Decision Systems Across Programs
Extend rigorous selection practices across multiple therapeutic areas.
12 chapters in this module
  1. Adapting frameworks for oncology versus chronic disease programs
  2. Customizing evidence thresholds by mechanism of action
  3. Standardizing templates while allowing therapeutic area flexibility
  4. Training new program teams on decision governance
  5. Implementing centralized oversight for portfolio consistency
  6. Creating playbooks for rare disease candidate evaluation
  7. Managing decentralized research units with common criteria
  8. Harmonizing data presentation formats across indications
  9. Building cross-program review boards for peer validation
  10. Establishing escalation processes for borderline candidates
  11. Sharing lessons learned from terminated programs
  12. Institutionalizing best practices across global development sites
Module 12. Leading Evolution of the Selection Function
Continuously improve the organization’s decision capability.
12 chapters in this module
  1. Measuring time-to-decision across candidate reviews
  2. Tracking accuracy of preclinical-to-clinical predictions
  3. Conducting post-mortems on terminated clinical candidates
  4. Benchmarking decision speed against peer organizations
  5. Soliciting feedback from clinical teams on selection quality
  6. Updating evidence thresholds based on clinical outcomes
  7. Investing in training for emerging modalities and technologies
  8. Evaluating new biomarker strategies for early signal detection
  9. Integrating real-world evidence into future selection models
  10. Refining stakeholder engagement protocols annually
  11. Publishing internal review of decision system performance
  12. Setting three-year goals for selection process maturity

Frequently asked

Who is this course designed for?
It is designed for chief development officers and senior leaders responsible for therapeutic candidate advancement decisions in biopharmaceutical organizations.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Does the course cover clinical trial design?
No, it focuses exclusively on the preclinical-to-clinical transition and the decision to advance a candidate, not on trial protocols or execution.
Is this about adopting a software platform?
No, it is about strengthening your internal decision processes, not implementing any specific technology or vendor solution.
Can teams participate together?
Yes, the course supports team enrollment with collaborative templates and group implementation guidance.
What formats do the templates come in?
The implementation playbook downloads as PDF and editable XLSX. The course reads in your learning environment and exports to PDF for offline use. The files are yours to keep.
Can I share this with my team?
The licence is per person. Team pricing opens from three seats: reply to the order confirmation with TEAM and we will set it up.
How quickly can I start?
The diagnostic is one sitting and the templates work straight out of the kit. Account access takes up to 24 hours rather than being instant, because every order is checked and updated against the latest sources before it is delivered.
$199 one-time. Approximately 3 hours per module, designed to be completed alongside active candidate reviews. Full course completion in 8–12 weeks with implementation..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee·Know your weakest area today·210 scored questions·Course included· Account access within 24 hours
30-day money-back guarantee, no questions asked.
Thousands of organisations have bought from The Art of Service since 2000.
!